Perrigo | PRGO - Sales Revenues


Perrigo reported $1.04B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Abbott USD 11.46B 90M Dec/2025
Bayer EUR 9.66B 1.08B Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Dr.Reddys Laboratories INR 87.27B 780M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
J&J USD 24.6B 610M Dec/2025
Merck USD 16.4B 880M Dec/2025
Nestle CHF 44.23B 2.08B Jun/2025
Pacira USD 179.52M 1.58M Sep/2025
Perrigo USD 1.04B 16.3M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Phibro Animal Health USD 309.26M 48.83M Dec/2024
Prestige Brands USD 283.44M 9.34M Dec/2025
Reckitt Benckiser GBP 3.3B 3.7B Jun/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Xeris Pharmaceuticals USD 74.38M 2.84M Sep/2025
Zoetis USD 2.4B 0 Dec/2025